News & Updates

Use of hydroxychloroquine (HCQ) does not contribute to the development of heart failure (HF) in patients with rheumatoid arthritis (RA), a study has shown.

Methotrexate (MTX) plus leflunomide (LEF) demonstrates a relatively good safety profile overall compared with the combination of MTX and sulfasalazine (SSZ) and strategies involving advanced therapies in rheumatoid arthritis (RA), reports a study.

A recent study has shown modest drug survival and primary response of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) switching due to failure of a nontumour necrosis factor inhibitor (non-TNFi) bDMARD as the first agent.

Current smoking reduces the response of patients with early rheumatoid arthritis (RA) to methotrexate (MTX) in a dose-responsive manner, regardless of concomitant prednisone use, a recent study has found.

The osteoporosis drug alendronate halves the risk of developing type 2 diabetes (T2D) in a nationwide, retrospective, case-control study of nearly 700,000 patients from Denmark.

Superficial needling acupuncture for 4 weeks does not appear to be more effective than nonpenetration sham acupuncture for knee osteoarthritis (OA), a study has found.

The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.

Among systemic lupus erythematosus patients, SARS-CoV-2-specific immune responses after BNT162b2 vaccination seem to be impaired in the presence of poor baseline humoral immune status, low naïve B cell frequencies, and mycophenolate mofetil (MMF) and methotrexate (MTX) use, according to a study.

The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.

Certain systemic diseases, such as Sjögren syndrome (SS), facial rosacea, rheumatoid arthritis (RA), and peripheral artery disease, and a history of daily cigarette smoking are significantly associated with more severe dry eye disease (DED) signs, a study has found.